Navigation Links
Targeting cancer with a triple threat
Date:4/15/2014

drug, doxorubicin, was designed so that it would be released only when ultraviolet light shines on the particle. Once all three drugs are released, all that is left behind is PEG, which is easily biodegradable.

Working with researchers in the lab of Paula Hammond, the David H. Koch Professor of Engineering and a member of MIT's Koch Institute for Integrative Cancer Research, the team tested the particles against ovarian cancer cells grown in the lab. Particles carrying all three drugs killed the cancer cells at a higher rate than those that delivered only one or two drugs.

Johnson's lab is now working on particles that carry four drugs, and the researchers are also planning to tag the particles with molecules that will allow them to home to tumor cells by interacting with proteins found on the cell surfaces.

Johnson also envisions that the ability to reliably produce large quantities of multidrug-carrying nanoparticles will enable large-scale testing of possible new cancer treatments. "It's important to be able to rapidly and efficiently make particles with different ratios of multiple drugs, so that you can test them for their activity," he says. "We can't just make one particle, we need to be able to make different ratios, which our method can easily do."


'/>"/>

Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Targeting enforcement where needed most in Africas heart of biodiversity
2. New therapies targeting cancer, Alzheimers goal of UH physicist
3. UTMB collaborates on program targeting potential bioterrorist pathogens Ebola and Marburg
4. Targeting metabolism to develop new prostate cancer treatments
5. Going against the flow: Halting atherosclerosis by targeting micro RNA
6. Targeting evolution: Could this be the next strategy to stop superbugs?
7. Targeting cancers sweet tooth
8. Honey bee gene targeting offers system to understand food-related behavior
9. U of M researchers develop model for better testing, targeting of MPNST
10. Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
11. Signalling pathways meeting targeting the HER/EGFR family: Focus on breast, lung and colorectal cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... last decade in Taiyuan, China, have substantially improved the ... than 50% reduction in costs associated with loss of ... researchers at the Columbia Center for Children,s Environmental Health ... Shanxi Medical University, the Center of Diseases Control and ... of Public Health. , The study is the first ...
(Date:9/2/2014)... others are done in by it. New research at ... so-called stress gap in mice with very similar genetic ... better understand the development of psychiatric disorders such as ... unique experiences as it goes through its life. And ... expression of genes, and as a result, affect an ...
(Date:9/1/2014)... that corals whose calcium-carbonate skeletons form the ... that rely entirely on ocean currents to deliver ... now scientists at MIT and the Weizmann Institute ... they are far from passive, engineering their environment ... enhance their ability to exchange nutrients and dissolved ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Nature's tiny engineers 2Nature's tiny engineers 3
... about how the human gut helps regulate our appetite have ... Scientists at the University of Cambridge are using the fruit ... pregnant women suffer from bloating and constipation, and even the ... scientists have known for some time that there are as ...
... MarylandThe American Association of Anatomist,s (AAA) will present its ... already made important contributions in their respective fields and ... will present an awards lecture at the AAA Annual ... 5-7 p.m., Walter E. Washington Convention Center, Washington, DC, ...
... This release is available in German . ... consumption is rising dramatically. Indeed, worldwide consumption of red meat ... Organization (FAO) expects increasing prosperity to lead to a doubling ... is whether our planet, with its limited farmland resources, will ...
Cached Biology News:Pregnant, constipated and bloated? Fly poo may tell you why 2Pregnant, constipated and bloated? Fly poo may tell you why 3American Association of Anatomists announces young investigator award winners 2Eating low-fat, thanks to lupin proteins 2
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Spherix Incorporated ... and monetization of intellectual property, today announced that the ... patents to the Company in the month of August ... patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and , ...
(Date:9/1/2014)... Reportlinker.com announces that a new market ... India Solid Waste Management Vehicles Market Forecast ... In India ... responsible for complete handling and regulation of solid ... 135,000 MT solid waste is generated daily in ...
(Date:8/31/2014)... N.J. , Aug. 31, 2014 Wockhardt ... Drug Discovery program in Anti-Infective research when two of ... coveted Qualified Infectious Disease Product (QIDP) status from U.S. ... to drugs which act against pathogens which have a ... are identified by Centre for Disease Control (a top ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... KOSN ) announced today that Gary S. Titus, ... at the 2007,UBS Global Life Sciences Conference in New ... at 10:00 a.m. EST. Interested parties may access ... Calendar" page under the "Investors/Press" tab on,Kosan,s website at ...
... SHENYANG, China, Sept. 18 /Xinhua-PRNewswire-FirstCall/ -- 3SBio ... biotechnology company focused on,researching, developing, manufacturing and ... General Meeting of Shareholders,of 3SBio Inc. will ... Wednesday, October 17,2007 at Tower B-13, Grand ...
... Biodel Inc. (Nasdaq:,BIOD) today announced additional clinical ... Scientific Sessions of the European Association for ... II meal study data was disclosed in ... pharmacodynamics of,insulin VIAject(TM), insulin lispro and regular ...
Cached Biology Technology:Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
Biology Products: